The management board has a supervisory role with general responsibility for budgetary and planning matters, the appointment of the Executive Director, and the monitoring of the Agency's performance.
EMEA Board
The management board has a supervisory role with general responsibility for budgetary and planning matters, the appointment of the Executive Director, and the monitoring of the Agency's performance.
European Commission
Heinz Zourek +32 2 299 80 01
Georgette Lalis +32 2 298 79 30
Isabel de la Mata +352 4301 33988
Bernard Merkel +32 2 299 21 00
European Parliament
Giuseppe Nisticò +9 36 63532608
Björn Lemmer +49 621 3839704
bjoern.lemmer@pharmtox.uni-heidelberg.de
Jozef Holomá +421 2 59369505
Austria
Marcus Müllner, +43 50 55536000
Christian Kalcher +43 1 711 00 48 94
Belgium
Xavier De Cuyper +32 2 5248400
André Lhoir +32 2 524 8080
Bulgaria
Elena Masseva +359 2 8903494
Cyprus
Panayiota Kokkinou +357 22 40 71 03
George Antoniou +357 22 407112
Czech Republic
Lenka Balážová +42 272 185203
Jiří Bureš +420 541 518275
Denmark
Jytte Lyngvig +45 44 88 95 55
Paul Schüder +45 33 92 32 24
Estonia
Kristin Raudsepp +372 7 37 41 40
kristin.raudsepp@ravimiamet.ee
Alar Irs +372 7 374 140
Finland
Pekka Järvinen +358 9 16 07 38 00
France
Marc Mortureux +33 1 49771350
Jean Marimbert +33 1 55 87 30 14
jean.marimbert@afssaps.sante.fr
Germany
Walter Schwerdtfeger +49 1888 441 1100
walter.schwerdtfeger@bmg.bund.de
Hans-Peter Hofmann +49 228 4411120
hans-peter.hofmann@bmg.bund.de
Greece
Dimitra Patargia +30 210 6507204
Hungary
Tamás L. Paál +36 1 88 69 320
Beatrix Horváth +36 1886 9320
Iceland
Ingolf J. Petersen +354 545 87 00
Rannveig Gunnarsdòttir +354 520 2100
rannveig.gunnarsdottir@imca.is
Ireland
Pat O'Mahony (chair) +353 1 634 34 53
Rita Purcell +353 1 634 3438
Italy
Guido Rasi +39 06 59784205
Silvia Fabiani +39 06 59 78 43 17
Latvia
Inguna Adovica +371 670 784 31
Dace Kikute +37 1 67078411
Liechtenstein
Brigitte Batliner +423 236 7325
Sabine Erne
Lithuania
Mindaugas Buta +370 5 212 4059
Jonas Milius +370 5 2780470
Luxembourg
Mariette Backes-Lies +352 478 55 90
mariette.backes-lies@ms.etat.lu
Claude Hemmer +352 478 55 20
Malta
Patricia Vella Bonanno +356 23 43 90 00
The Netherlands
Aginus A.W. Kalis +31 70 3567450
Rob De Haan
Norway
G. Ramsten Wesenberg +47 22 897700
gro.wesenberg@legemiddelverket.no
Hans Halse +47 22 897705
Poland
Wojciech Matusewicz +48 22 5667200
Jacek Splawinski +48 22 841 04 10
Portugal
A.J. Maria Rui Vasco +351 21 798 71 09
F. Manuel d'Almeida +351 21 3239654
subdirgeral@dgv.min-agricultura.pt
Romania
Daniel Boda +40 21 3171102
Slovakia
Jan Mazag +421 2 50701 119
Dagmar Stará +421 2 50 70 12 51
Slovenia
Martina Cvelbar +386 8 2000508
Vesna Koblar +386 8 2000502
Spain
C. Avendaño-Solà +34 91 8225028
L. Franqueza García+34 91 8225040
Sweden
Christina Åkerman +46 18 174600
Johan Lindberg +46 8 4052077
johan.lindberg@social.ministry.se
United Kingdom
Kent Wood +44 20 70842546
Steve Dean +44 1932 338301
Patient organizations
Mike O'Donovan +44 (0)1344 623680
M.G. Baker +44 1483 763626
Doctors
Lisette Tiddens-Engwirda +32 2 732 72 02
Information current as of 11/09
Emails available in online edition
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.